← Back to headlines
Recursion outlines 2026 cash OpEx guidance and advances Genentech target
Recursion has outlined its 2026 cash operating expenses guidance at $375 million. The company is also advancing its first neuroscience target in collaboration with Genentech.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
